Dermata Therapeutics reports FY2022 cash of $6.2M; plans DMT310 Phase 3 in 2H 2023

Dermata Therapeutics, Inc.

Cash and equivalents $6.2M at Dec 31, 2022, down from $10.8M a year earlier.
R&D expenses $5.7M in FY2022 vs $3.5M in FY2021, driven by DMT310 clinical/CMC costs.
Cash expected to fund operations into Q3 2023; no revenue reported.
End-of-Phase 2 meeting with FDA for DMT310 (acne) expected in Q2 2023; Phase 3 start in H2 2023.
DMT410 partnership discussions ongoing for topical botulinum toxin delivery.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Dermata Therapeutics, Inc. reported financial results for the year ended December 31, 2022.

Period: the year ended December 31, 2022
Result: reported results

Exact text from the filing

On February 21, 2023, Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the fiscal year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Dermata Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-23-001927

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.